April 24, 2013
Adapting to a Rapidly Changing Environment (Ernst & Young Beyond Borders 2013).
April 17, 2013
Women Leaders in Biotech: 'Walls are coming down' (Bioworld Today).
March 07, 2013
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1) in Solid Tumors.
March 04, 2013
Tosedostat Opal Study In Acute Myeloid Leukaemia Published In Lancet Oncology.
January 28, 2013
Idenix Pharmaceuticals Announces Collaboration with Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) And TMC647055 for the Treatment of Hepatitis C Virus (HCV).
January 03, 2013
Chroma Therapeutics Advance Novel Targeted Agent Towards Clinical Development; Receives Milestone Payment and Extends Collaboration with GSK.
October 04, 2012
OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical Development.
July 20, 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis™ (carfilzomib) for Injection.
July 3, 2012
Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB.
June 21, 2012
Onyx Pharmaceuticals' Kyprolis™ Receives Positive Vote From Oncologic Drugs Advisory Committee (ODAC).
June 1, 2012
Forest Laboratories and Nabriva Therapeutics Sign Agreement.
May 10, 2012
Citi Appointed By Phase4 Ventures To Handle Private Equity Fund Administration.
April 3, 2012
Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixbat.
December 13, 2011
Chroma Therapeutics and its Partner Cell Therapeutics Announced Final Results from the Phase II OPAL Study of Tosedostat in Elderly Patients with Relapsed or Refractory AML were Presented at ASH.
November 29, 2011
Onyx Pharmaceuticals Announces FDA Acceptance of New Drug Application for Carfilzomib for the Treatment of Relapsed and Refractory Multiple Myeloma.
October 10, 2011
Zosano Pharma Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement.
September 28, 2011
Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma.
September 15, 2011
Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781.
June 7, 2011
Chroma Therapeutics Announces New Positive Interim Phase II Data for Tosedostat in AML OPAL Study.
April 28, 2011
OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5.
April 18, 2011
Nabriva Therapeutics Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI.
March 14, 2011
Chroma Therapeutics and Cell Therapeutics Enter into a Collaboration to Develop and Commercialise Tosedostat, a First in Class Tumour Selective Oral Anti-Cancer Therapy.
February 8, 2011
Phase4 Ventures Spins Out from Nomura and Partners with HarbourVest Partners to Acquire a Portfolio of Investments.
January 31, 2011
Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval.
January 20, 2011
Evotec to Collaborate with Takeda Cambridge for Multitarget Hit Identification.
January 13, 2011
Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim.
January 10, 2011
Nabriva Completes Recruitment of Phase II of Pleuromutilin Antibiotic BC-3781.
January 10, 2011
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5.
January 6, 2011
Chroma Therapeutics to Present at 29th Annual J.P. Morgan Healthcare Conference.
December 15, 2010
Evotec Announces Metabolic Disease Alliance with MedImmune.
October 12, 2010
Albireo Announces Positive Results in Patients with Chronic Idiopathic Constipation from a Phase IIb Trial of A3309.
September 10, 2010
Nabriva Therapeutics Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections with Both Oral and IV Dosing in Non-Clinical and Clinical Phase I Studies.
September 2, 2010
Evotec Completes Acquisition of DeveloGen.
July 14, 2010
Evotec Strengthens Discovery Alliance Business Through Acquisition of DeveloGen.
June 17, 2010
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics.
June 2, 2010
Nabriva Initiates Phase II of Pleuromutilin Antibiotic BC-3781.
April, 16, 2010
Idenix Pharmaceuticals Reports Favourable Pharmacokinetic Data for IDX320, A Potent, Multi-Genotypic Protease Inhibitor For The Treatment of Hepatitis C.
April, 15, 2010
Idenix Pharmaceuticals Reports Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study.
April, 12, 2010
Nabriva Reports Successful Phase I Clinical Trial For BC-3781.
January 11, 2010
Idenix Pharmaceuticals Highlights Progress In Three HCV Programs.
December 3, 2009
AstraZeneca and Targacept Form Global Collaboration and License Agreement for Late-stage Investigational Product TC-5214 for the Treatment of Major Depressive Disorder.
December 2, 2009
Phenomix Grants Chiesi Farmaceutici European Rights to Dutogliptin for Diabetes.
November 9, 2009
Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of Its ZP PTH Patch For Osteoporosis Therapy.
October 28, 2009
Nabriva Therapeutics raises Euro 15 Million (USD22 Million).
October 12, 2009
Proteolix, Inc To Be Acquired by Onyx Pharmaceuticals.
October 8, 2009
Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3.
July 20, 2009
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 For The Treatment of Hepatitis C Virus (HCV).
July 15, 2009
Targacept's TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder.
June 23, 2009
GSK and Chroma Therapeutics Form Alliance to Develop Novel Macrophage-Targeted Drugs.
June 23, 2009
Chroma Therapeutics Completes £15 Million Series D Financing.
May 13, 2009
Boehringer Ingelheim and DeveloGen AG Announce Agreement in the Field of Diabetes, Obesity and the Metabolic Syndrome.
May 11, 2009
Targacept Announces Positive Top-Line Results from Phase II Study of AZD3480 in Adult ADHD.
May 7, 2009
Nabriva Therapeutics Appoints New Supervisory Board Member.
May 4, 2009
ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America.
April 23, 2009
Idenix Pharmaceuticals Reports Data from Three Hepatitis C Development Programs.
March 25, 2009
Acadia Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs.
February 26, 2009
DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173.
February 25, 2009
Proteolix Announces the Appointment of John Scarlett, MD, President and CEO.
February 6, 2009
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, A Novel NNRTI for the Treatment of HIV.
January 28, 2009
Nomura Phase4 Ventures named Venture Capital House of the Year.
December 9, 2008
Proteolix Announces Positive Data from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma.
November 4, 2008
OncoMed Pharmaceuticals Completes Series B Financing; Lead Cancer Stem Cell Product Enters Clinical Trials.
October 30, 2008
Top City Women Scoop Prestigious Awards.
October 23, 2008
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes.
September 12, 2008
Ominsonics Medical Technologies Announces Licensing and Development Agreement with Boston Scientific.
September 11, 2008
Zosano Pharma, Inc. Announces Positive Results of Phase 2 Trial with PTH Transdermal Patch in Osteoporosis.
September 11, 2008
Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of its Diclofenac Sodium Patch for Acute Pain.
September 8, 2008
Proteolix Raises $79 Million in Series C Financing.
September 8, 2008
Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO.
September 4, 2008
Idenix Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naïve HIV-Infected Patients.
July 7, 2008
Nabriva Therapeutics Announces Appointment of George Golumbeski as CEO.
June 17, 2008
Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals Extend and Expand Drug Discovery Collaboration for Spinal Muscular Atrophy.
June 17, 2008
ARYx Therapeutics Inc Commences Phase2/3 Clinical Trial on Oral Anticoagulant Agent ATI-5923 – EmbraceAC Comparative Study Against Leading Anticoagulant Warfarin.
June 12, 2008
Idenix Announces Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naïve HIV-Infected Patients.
May 22, 2008
Altus Pharmaceuticals Appoints Georges Gemayel Chief Executive Officer and Member of Board of Directors.
May 16, 2008
Phenomix Announces PHX1149 Phase2b Clinical Trial Results for Type 2 Diabetes.
May 7, 2008
Albireo Announces Second Closing of Series A Financing.
April 16, 2008
Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections.
March 31, 2008
ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis.
March 24, 2008
Nomura Phase4 Ventures' Feature in BioCentury: Clear route to Phase IIb.
February 14, 2008
Nomura Phase4 Ventures Leads Spin Out of Albireo from AstraZeneca, Raising up to US$40 in Series A Equity Financing.
February 6, 2008
IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a PhaseI/II Clinical Trial in Treatment Naive HIV-Infected Patients.
January 25, 2008
Phenomix Files Registration Statement For Proposed Initial Public Offering.
January 16, 2008
Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate Its Diclofenac Patch for Mild to Moderate Pain.
January 7, 2008
Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline.
December 19, 2007
Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialization Rights.
December 13, 2007
Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797.
December 3, 2007
Targacept Announces Results of Phase II Study of TC-2696 in Postoperative Dental Pain.
November 15, 2007
PerkinElmer Completes Acquisition of Viacell.
November 15, 2007
Zosano Pharma Announces Funding Close Totaling $90 Million.
November 7, 2007
ARYx Therapeutics Announces Pricing of its Initial Public Offering.
November 5, 2007
Targacept to Receive $2 Million from AstraZeneca for Option to Lead Product Candidate in Alpha7 NNR Program.
October 25, 2007
Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections.
October 8, 2007
OmniSonics Announces that FDA Clears OmniWave Endovascular System for Clot Removal in Peripheral Vessels.
October 1, 2007
PerkinElmer to Expand Genetic Screening Business Through Acquisition of ViaCell.
September 28, 2007
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs.
September 27, 2007
Macroflux Announces Name Change to Zosano Pharma, Inc.
September 20, 2007
Viacell Announces that Children Can be Cured of Sickle Cell Disease and Thalassemia After Sibling Cord Blood Transplantation.
September 18, 2007
ViaCell Announces Expansion of ViaCord Processing Laboratory.
September 4, 2007
ViaCell Announces ViaCyte Collaboration with EMD Serono, Inc.
August 30, 2007
ARYx Therapeutics Files Registration Statement for Initial Public Offering.
August 14, 2007
Nabriva Announces the Initiation of Clinical Phase1 Study for Topical Antibiotic.
August 14, 2007
Altus Pharmaceuticals' ALTU-237 Enters Phase I Clinical Trial for the Treatment of Hyperoxalurias and the Potential Prevention of Kidney Stone Formation.
July 27, 2007
Targacept and GlaxoSmithKline Form Alliance in Therapeutics for CNS-related Disorders.
July 16, 2007
ACADIA Pharmaceuticals Earns Milestone on Advancement of Glaucoma Drug Candidate.
July 13, 2007
Idenix's Valopicitabine Development Program Placed on Clinical Hold in the United States.
July 9, 2007
Paratek Pharmaceuticals and Warner Chilcott Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea.
March 8, 2007
Nomura Phase4 Ventures leads a US$55 million Series C equity financing of Phenomix Corporation.